What is the treatment for erosive antral gastritis with a positive Rapid Urease Test (RUT) indicating Helicobacter pylori (H. pylori) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Erosive Antral Gastritis with Positive RUT

For erosive antral gastritis with confirmed H. pylori infection (RUT positive), initiate 14-day bismuth quadruple therapy as first-line treatment, consisting of a high-dose PPI (omeprazole 40 mg or equivalent twice daily), bismuth, tetracycline, and metronidazole. 1, 2

First-Line Treatment Regimen

Bismuth quadruple therapy is the preferred empirical first-line treatment for H. pylori eradication in the current era of rising antibiotic resistance 1. This regimen includes:

  • High-dose PPI twice daily: Use omeprazole 40 mg, esomeprazole 20-40 mg, or rabeprazole 20-40 mg twice daily (avoid pantoprazole due to lower potency) 3
  • Bismuth subsalicylate or bismuth subcitrate: Standard dosing four times daily 1, 2
  • Tetracycline: 500 mg four times daily 2
  • Metronidazole: 500 mg three times daily or 250 mg four times daily 4, 5
  • Duration: 14 days 1, 2

The rationale for bismuth quadruple therapy is that bacterial resistance to bismuth is extremely rare, making this regimen effective even against clarithromycin-resistant strains 2.

Alternative First-Line Option (Region-Dependent)

In areas with documented low clarithromycin resistance (<15%), triple therapy may be considered, though this is increasingly uncommon 1. The regimen consists of:

  • PPI: High-dose twice daily (omeprazole 40 mg or equivalent) 3
  • Clarithromycin: 500 mg twice daily 6
  • Amoxicillin: 1000 mg twice daily 6
  • Duration: 10-14 days (14 days preferred for improved eradication rates) 4

However, standard triple therapy should be abandoned in regions with clarithromycin resistance >15-20% due to unacceptably low eradication rates 1.

Enhanced Quadruple Therapy Alternative

Concomitant quadruple therapy (all antibiotics simultaneously) for 5-10 days is another effective option 4:

  • PPI: High-dose twice daily 3
  • Amoxicillin: 1000 mg twice daily 4
  • Clarithromycin: 500 mg twice daily 4
  • Metronidazole: 500 mg twice daily 4

This achieves approximately 90% eradication rates compared to 80% with standard triple therapy 4.

Critical Treatment Optimization Factors

PPI Dosing

High-dose PPI (twice daily) is non-negotiable as it significantly increases eradication efficacy by 6-10% compared to standard doses 1, 2. The PPI reduces gastric acidity, promoting logarithmic phase bacterial growth and enhancing antibiotic penetration 3.

Treatment Duration

Extending treatment from 7 to 14 days improves eradication success by approximately 5-10% 1, 4. Always prescribe 14-day regimens when possible.

Antibiotic Selection

Avoid antibiotics the patient has previously received, particularly clarithromycin and levofloxacin, as resistance develops rapidly 2. Clarithromycin resistance has increased globally from 9% in 1998 to 17.6% in 2008-2009 1.

Second-Line Treatment After First-Line Failure

After failure of clarithromycin-containing therapy, use bismuth quadruple therapy (if not previously used) or levofloxacin-containing triple therapy 1:

  • Levofloxacin triple therapy: PPI twice daily + amoxicillin 1000 mg twice daily + levofloxacin 500 mg once daily (or 250 mg twice daily) for 14 days 1

After two failed eradication attempts, antimicrobial susceptibility testing should guide further treatment whenever possible 2, 3. Culture and sensitivity testing is particularly important when endoscopy is performed for other indications 3.

Verification of Eradication

Confirm eradication with urea breath test or monoclonal stool antigen test at least 4 weeks after completion of therapy and at least 2 weeks after PPI discontinuation 1, 2.

Do not use serology to confirm eradication as antibodies persist long after successful treatment 1, 2.

For erosive gastritis specifically, endoscopic follow-up may be warranted to document mucosal healing and exclude underlying malignancy, particularly in gastric (versus duodenal) erosions 3.

Common Pitfalls to Avoid

  • Inadequate PPI dosing: This is the most common error; always prescribe twice-daily high-dose PPI 1, 2
  • Testing too early: Wait at least 4 weeks post-treatment and 2 weeks off PPIs before testing for eradication 1, 2
  • Using PPIs before diagnostic testing: PPIs should be stopped 2 weeks before RUT, histology, culture, or breath testing as they cause false-negative results 3
  • Repeating failed antibiotics: Never reuse clarithromycin or levofloxacin after treatment failure 2
  • Short treatment duration: Seven-day regimens are no longer adequate; use 14-day courses 1, 4

Special Considerations for Erosive Antral Gastritis

Erosive antral gastritis with H. pylori represents the duodenal ulcer phenotype, characterized by antral-predominant inflammation and high acid output 7. This pattern responds well to H. pylori eradication, which reduces both gastritis activity and erosion recurrence 7, 8.

The erosions themselves do not change the antibiotic regimen but emphasize the importance of successful eradication, as H. pylori-positive patients with erosions have a 38% recurrence rate at 17 years versus 11% in controls 7.

References

Guideline

H. pylori-Related Pain Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for Persistent Helicobacter pylori Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Helicobacter pylori and gastric or duodenal ulcer.

Prescrire international, 2016

Research

Evolution of gastritis in patients with gastric erosions.

Scandinavian journal of gastroenterology, 2005

Research

Azithromycin for the cure of Helicobacter pylori infection.

The American journal of gastroenterology, 1996

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.